Background: HIV preferentially depletes CD4 T cells in the gut-associated lymphoid tissue during acute infection, likely associated with high levels of CCR5 expression. Maraviroc (MVC) blocks HIV entry by binding CCR5. The consequences of MVC treatment on the gut microbiome have not been investigated. Here, we evaluated the impact of antiretroviral treatment (ART) plus MVC intensification on the gut microbiome during primary HIV infection.
Methods: Thirteen recently HIV infected persons in the San Diego Primary Infection Cohort were randomized to receive early ART (atazanvir, ritonavir, tenofovir and emcitritabine) with or without MVC. Anal swabs were collected prior to the start of ART and approximately every 4 weeks thereafter for 48 weeks. Stool DNA was extracted from the swabs and the V6 region of the 16s rDNA gene was pyrosequenced. We classified bacterial sequences at the order level and evaluated microbiome profile differences cross-sectionally and longitudinally between persons who did (MVC+) or did not (MVC-) receive MVC. All analyses were performed with R statistical software.
Results: We classified 13 orders of bacteria that were shared among all participants at baseline. We then compared each order of bacteria between MVC+ (n=6) and MVC- (n=7) individuals at weeks 4, 24, and 48 after initiation of ART. The distribution of bacterial orders between groups did not differ statistically (p>0.05) at any time point (Mann-Whitney test). In a paired analysis comparing baseline bacterial levels with weeks 4, 24, and 48 between MVC groups, we found no differences in the levels of each order of bacteria (Wilcoxon test); however, there was a trend for a reduction of the order of Actinomycetales from baseline to week 48 (p=0.06). When we evaluated the full microbiome of all participants at all time points measured using principal component analysis, there were no clusters based on MVC intensification (see figure).
Conclusions: In early HIV infection, CCR5 blockade with MVC may be a potent antiviral strategy for reducing the depletion of CD4 lymphocytes in the gut but, it does not significantly alter the gut microbiome. As such, Maraviroc may be a beneficial addition to treatment strategies involving reshaping the gut microbiome.
Principal component analysis of the gut microbiome of patient samples obtained at each timepoint. Each dot, labeled with a letter followed by a number, corresponds to a single sample in which each letter (A through M) corresponds to a patient and the number (0 through 48) identifies at which week the sample was taken. Red points belong to the MVC- group and blue points belong to the MVC+ group. There is no evidence of clusting by MVC group.